MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes
|
|
- Franklin Mills
- 5 years ago
- Views:
Transcription
1 MedDRA 13.0 Review MedDRA Version Changes General Remarks MedDRA Version 13.0 Specific Changes Version 13.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 13.0 Terminology Frequency Distribution MedDRA Version What's coming ahead?
2 MedDRA Changes - General Remarks There are two possible types of changes in the MedDRA terminology: simple changes and complex changes. Simple changes are changes to the existing terminology that involve terms at the PT and LLT levels. There are two types of Simple changes: (1) changes introduced by subscribers request and (2) Maintenance changes (also referred to as Associate changes). Maintenance changes are generated as a by-product of other changes requested by subscribers, or changes introduced by the MedDRA Management Board to preserve consistency within the dictionary. Complex changes involve modifications within the entire hierarchy, including the HLT, HLGT, and SOC terminology. Currently, the initial MedDRA terminology version release in one specific year (12.0, 13.0) includes both simple and complex changes, and the subsequent release in the same year (12.1, 13.1) represents a simple change of terminology. These changes are based on MedDRA subscribers' terminology change requests and on MedDRA terminology maintenance needs identified by MedDRA's maintenance organization reviewers. Please note that as a consequence of implementing some of these changes (e.g. demoting a multiaxial PT, adding a new HLT, etc.) it may be necessary to break the multiaxial links, to re-link the replacement terms, and/or to enable additional terms to be included within a particular SOC. All these changes may require modifications to your existing MedDRA coding, guideline development, and data retrieval practices. Keep in mind that changes involve both MedDRA terminology updates as well as Standardized MedDRA Queries (SMQ). Back to MedDRA 13.0 Review
3 MedDRA 13.0 Changes: Overview Changes In a Nutshell Complex Changes New Device related and Microorganism terms Standardized MedDRA Queries (SMQs) Changes Highlights Featured PT Changes New PTs Promoted LLTs Featured LLT Changes New LLTs Demoted PTs Currency changes Back to MedDRA 13.0 Review
4 Changes In a Nutshell Complex Changes The complex changes implemented in Version 13.0 are summarized below. At the SOC level: No changes were made to existing SOC terms and no new SOCs were added in Version 13.0 At the HLGT level: There were 3 HLGT s added and 1HLGT merged as a result of the complex changes in Version They are as follows: New HLGT s Complications associated with device to SOC General disorders and administration site conditions Device issues to SOC General disorders and administration site conditions Procedural related injuries and complications NEC to SOC Injury, poisoning and procedural complications Merged HLGT s Procedural and device related injuries and complications NEC to HLGT Procedural related injuries and complications NEC Modified HLGT Names There were no modified HLGTs in Version 13.0 At the HLT level: There were 17 new High Level Terms (HLTs) added and 7 HLTs merged as a result of the complex changes in Version They are as follows: New HLT s Breast complications associated with device to HLGT Complications associated with device Cardiac complications associated with device to HLGT Complications associated with device Cerebrospinal fluid therapeutic procedures to HLGT Nervous system, skull and spine therapeutic procedures Complications associated with device NEC to HLGT Complications associated with device Device computer issues to HLGT Device issues Device electrical issues to HLGT Device issues Device incompatibility issues to HLGT Device issues Device information output issues to HLGT Device issues Device issues NEC to HLGT Device issue Device malfunction events NEC to HLGT Device issues Device operational issues NEC to HLGT Device issues Device physical property and chemical issues to HLGT Device issues Eye complications associated with device to HLGT Complications associated with device Reproductive complications associated with device to HLGT Complications associated with device Respiratory complications associated with device to HLGT Complications associated with device Thrombocytoses to HLGT Platelet disorders Vascular complications associated with device to HLGT Complications associated with device Merged HLT s
5 Calymmatobacteria infections to HLT Klebsiella infections Cerebrospinal fluid shunt therapeutic procedures to HLT Cerebrospinal fluid therapeutic procedures Device component findings to HLT Device issues NEC Device malfunction events to HLT Device malfunction events NEC Device related complications to HLT Complications associated with device NEC Paracolon bacillus infections to HLT Bacterial infections NEC Secondary thrombocythaemias to HLT Thrombocytoses Back NEW DEVICE RELATED AND MICROORGANISM TERMS NEW DEVICE RELATED TERMS New device related HLGTs and HLTs were added to SOC General disorders and administration site conditions where HLGT Product quality issues is linked. Existing device related HLTs under SOC Injury, poisoning and procedural complications were merged under corresponding new HLTs added to SOC General disorders and administration site conditions. Existing device related PT/LLT terms were moved from SOC Injury, poisoning and procedural complications to the appropriate new device HLTs and new approved device PT/ LLT terms were added. Of the 300 device related term changes proposed, 279 changes were approved, including the addition of 58 new terms, and 21 changes were rejected. The remainder of the approved changes consisted of movement of existing terms, changes in hierarchy (e.g., demotions of PTs) and changes to the currency status of LLTs. Some examples of new PT s added under HLGT Device issues are: Device alarm issue Device capturing issue Device chemical property issue Device colour issue Device component issue Device computer issue NEW MICROORGANISM TERMS A regulatory authority that uses MedDRA proposed a set of microorganism terms to capture identification (by a test) of an organism when there is no documented infection. As a result, a total of 371 new PT and LLT terms were added and 194 existing terms were moved (e.g., demoted PTs, promoted LLTs, LLTs moving from one PT to another, etc.) Terms added have the organism name with a test positive modifier at the end of the term (e.g. PT Brucella test positive). To avoid having two very close concepts represented at the PT level, existing identified/test positive PT terms were demoted under corresponding new PTs and are now LLTs. Similarly, existing serology / test positive PT terms have been demoted to LLTs under corresponding new microorganism test positive PTs. Below are several examples.
6 Existing PT in MedDRA v12.1 New PT added in MedDRA v13.0 LLTs in MedDRA v13.0 Chlamydia identification test positive Chlamydia test positive Chlamydia identification test positive Brucella serology positive Brucella test positive Brucella serology positive Legionella serology positive Legionella test positive Legionella serology positive The modifier test positive implies that an organism had been identified, but what is often performed especially for clinical viral disease is a measurement of a titer, viral load, etc. To capture various measurements, broad concept terms such as PT Viral titre increased, PT Viral titre decreased, and PT Viral titre were added for MedDRA v13.0. For consistency with the new test positive terms, new PTs were added for existing negative and unqualified test/serology terms which were demoted under these new PTs. Below are some examples. Existing PT in MedDRA v12.1 New PT added in MedDRA v13.0 LLTs in MedDRA v13.0 Borrelia burgdorferi serology negative Brucella serology negative Borrelia test negative Brucella test negative Borrelia burgdorferi serology negative Brucella serology negative Brucella serology Brucella test Brucella serology Microorganism Test Negative/Unqualified Terms Back Standardized MedDRA Queries (SMQs) A total of 3 new level 1 SMQs were released into production in MedDRA Version There are now 82 level 1 SMQs in production as of this version. The new SMQs are listed below. SMQ Name Osteonecrosis (SMQ) Renovascular disorders (SMQ) Scleral disorders (SMQ) In addition to three new SMQs, the scope of PTs in Gastrointestinal perforation, ulceration, haemorrhage or obstruction (SMQ) (except those under sub-smq
7 Gastrointestinal perforation, ulcer, haemorrhage, obstruction non-specific findings/procedures (SMQ)) and Oropharyngeal disorders (SMQ) changed from broad to narrow after a review by the CIOMS Working Group and the MSSO. The table below lists the sub-search SMQs affected. Level 1 SMQ Oropharyngeal disorders (SMQ) Scope Changes to PTs in Sub-Search SMQs Gingival disorders (SMQ) Oropharyngeal allergic conditions (SMQ) Gastrointestinal perforation, ulceration, haemorrhage or obstruction (SMQ) Oropharyngeal infections (SMQ) Oropharyngeal lesions, non-neoplastic, non-infectious and non-allergic (SMQ) Oropharyngeal neoplasms (SMQ) Gastrointestinal haemorrhage (SMQ) Gastrointestinal obstruction (SMQ) Gastrointestinal perforation (SMQ) Gastrointestinal ulceration (SMQ) Back Back to MedDRA 13.0 Review
8 MedDRA Version 13.0 Specific Changes Changes Highlights Featured PT Changes PT Changes: new PTs - 20 Promoted LLTs demoted PTs - Net new 145 PTs Net change of PTs equals the number of new PTs plus the number of promoted LLTs minus the number of demoted PTs. VERSION 13.0 Following are several examples: Hydrolipoclasy Internal fixation of spine Intestinal stent removal Laryngeal dilation procedure Low carbohydrate diet Lung wedge resection Vitreal cells Vitreous floaters Submaxillary gland enlargement Device expulsion Device extrusion New PT New PT New PT New PT New PT New PT Promoted LLT Promoted LLT Promoted LLT Promoted LLT Promoted LLT Back
9 Featured LLT Changes New LLTs there was a net change of 755 new LLTs Demoted PTs 246 PTs were demoted to LLT level in version 13.0 Currency changes 16 LLTs had a currency change in version 13.0 from current to non-current Modified LLTs- 25 LLTs were modified No LLTs changed from non-current to current status LLT Version 13.0 Currency Non-current Brahma forest enterovirus antibody test Non-current Cold Non-current Drug implant rejection Non-current Extrapyramidal disorder aggravate Non-current HTLV-I Mechanical complication due to coronary bypass Non-current graft Non-current Intrauterine device disorder LLT Currency Changes (partial) The following table partially lists LLTs that were modified (renamed) to correct for misspelling, double spacing, capitalization or other valid errors that meet the renaming criteria in MedDRA. This rename provision retains the original MedDRA code of the term and preserves its original meaning. This facilitates the reuse of the same MedDRA code for the renamed PT / LLTs. Level Code Term name in v12.1 Term name in v13.0 LLT Echo virus serology Echovirus serology LLT LLT Group A betahaemolytic streptococcal positive Group A betahemolytic streptococcal positive Group A beta haemolytic Streptococcus positive Group A beta hemolytic Streptococcus positive
10 LLT LLT LLT LLT LLT LLT LLT LLT LLT Group B betahaemolytic streptococcal negative Group B betahaemolytic streptococcal positive Group B betahaemolytic streptococcal test Group B betahemolytic streptococcal negative Group B betahemolytic streptococcal positive Group B betahemolytic streptococcal test Methicillin-resistant staphylococcal aureus test Methicillin-resistant staphylococcal aureus test negative Methicillin-resistant staphylococcal aureus test positive Group B beta haemolytic Streptococcus negative Group B beta haemolytic Streptococcus positive Group B beta haemolytic Streptococcus test Group B beta hemolytic Streptococcus negative Group B beta hemolytic Streptococcus positive Group B beta hemolytic Streptococcus test Methicillin-resistant Staphylococcus aureus test Methicillin-resistant Staphylococcus aureus test negative Methicillin-resistant Staphylococcus aureus test positive LLT Ramsey-Hunt syndrome Ramsay-Hunt syndrome LLT Staphylococcal identification test Staphylococcus identification test LLT Staphylococcal identification test negative Modified LLTs (partial list) Staphylococcus identification test negative Back Back to MedDRA 13.0 Review
11 MedDRA Version 13.0 Terminology Frequency Distribution by MedDRA Version Level Version Version Version Version Version Version Version Version Version SOC HLGT HLT 1,682 1,682 1,682 1,682 1,688 1,688 1,699 1,699 1,709 PT 17,320 17,505 17,719 17,867 18,075 18,209 18,483 18,641 18,786 LLT 63,817 64,620 65,147 65,605 66,135 66,587 67,159 67,503 68,258 Current LLT's 54,834 55,621 56,125 56,580 57,104 57,556 58,124 58,451 59,190 Non-current LLT's 8,983 8,999 9,022 9,025 9,031 9,031 9,035 9,052 9,068 : For complete downloads please check on the following MSSO link: Back to MedDRA 13.0 Review
12 MedDRA Version What's Coming Ahead? The next MedDRA terminology release, version 13.1, is scheduled for September Back to MedDRA 13.0 Review
MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell
MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 14.0 Terminology Frequency
More informationWhat s New MedDRA Version 13.1
What s New MedDRA Version 13.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered
More informationWhat s New MedDRA Version March
C What s New MedDRA Version 21.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is registered by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and
More informationWhat s New MedDRA Version March
c What s New MedDRA Version 20.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationWhat s New MedDRA Version 14.0
What s New MedDRA Version 14.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered
More informationWhat s New MedDRA Version 18.0
What s New MedDRA Version 18.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationOverview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)
Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Judy Harrison Chief Medical Officer MedDRA MSSO 22 October 2013 MedDRA Data
More informationWhat s New MedDRA Version 15.1
What s New MedDRA Version 15.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationWhat s New MedDRA Version MSSO-DI March 2016
c What s New MedDRA Version 19.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationMedDRA Basic Concept
MedDRA Basic Concept Pansie Zhang MSD R&D (China) Co., Ltd 23Apr2015 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not
More informationMedDRA Overview A Standardized Terminology
MedDRA Overview A Standardized Terminology Patrick Revelle Director, MedDRA MSSO 6 May 2010 MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.6 Based on MedDRA Version 16.1 1 October 2013 Disclaimer and Copyright Notice This
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.14 Based on MedDRA Version 20.1 1 September 2017 Disclaimer and Copyright Notice
More informationMedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know
MedDRA 10.1 Review MedDRA Version Changes General Remarks Terminology Files: What you need to know MedDRA Version 10.1 Specific Changes Version 10.1 Changes Overview Changes in a Nutshell Changes Highlights
More informationImplemented MedDRA Version 22.0 Complex Changes (October 2018)
Implemented MedDRA Version 22.0 Complex Changes (October 2018) MedDRA User Proposed Requests: 1. Move HLT Cardiac disorders NEC from HLGT Cardiac disorder signs and symptoms to new HLGT Cardiac disorders
More informationProposed MedDRA Version 17.0 Complex Changes (July 2013)
Proposed MedDRA Version 17.0 Complex Changes (July 2013) MedDRA User Submitted Requests: 1. Add a new HLT Exserohilum infections to HLGT Fungal infectious disorders Submitter rationale: Adding this HLT
More informationData retrieval using the new SMQ Medication Errors
Data retrieval using the new SMQ Medication Errors Christina Winter Medical Director Safety Evaluation and Risk Management, GSK Information Day on Medication Errors 20 October 2016 London, UK Disclaimer
More informationUse of MedDRA in Special Situations
Use of MedDRA in Special Situations Patrick Revelle MedDRA MSSO 13 March 2012 Overview Existing terms in MedDRA for off-label use, abuse, misuse, overdose, and medication errors Current coding recommendations
More informationPreview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations
Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Judy Harrison, M.D. Chief Medical Officer MedDRA MSSO Information Day on Medication Errors 20 October 2016 London,
More informationData Analysis and Query Building with MedDRA
Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The
More informationPerspective: E2B transmission
Perspective: E2B transmission I2B(M) Information about the safety report itself A.1 Report identification A.2 Primary source of information A.3.1 Who sends the information A.3.2 Who receives it Case information
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release draft Based on MedDRA version 7.1 ICH-Endorsed Guide for MedDRA Users on Data Output 18 November 2004 Copyright ICH Secretariat (c/o IFPMA)
More informationSafety Data Analysis and Query Creation with MedDRA
Safety Data Analysis and Query Creation with MedDRA Anne Kehely & Eva Rump Eli Lilly/MSSO 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Insert your logo in this area then delete this text
More informationIntroductory Guide MedDRA Version 15.0
Introductory Guide MedDRA Version 15.0 Acknowledgements Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory
More informationBest practices in VeDDRA coding
Best practices in VeDDRA coding 27 November 2013 Presented by: Giles Davis Chair of PhVWP-V VeDDRA sub-group An agency of the European Union Veterinary Dictionary for Drug Related Affairs SOC = System
More informationIntroductory Guide MedDRA Version 14.0
Introductory Guide MedDRA Version 14.0 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory
More informationIntroduction to MedDRA
Introduction to MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationWHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.
WHO-ART Magnus Wallberg November 24 th 2009 Dar Es Salaam, Tanzania magnus.wallberg@who-umc.org WHO-ART (WHO-Adverse Reaction Terminology) The need for a medical terminology dyspnoea? tinnitus ARDS fever
More informationData Analysis and Query Building with MedDRA
Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The
More informationFarmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.
Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI 23-24 EKİM 2003 Dr. Tomás Moraleda Agenda 1. What is MedDRA? 2. Conditions before MedDRA 3. MedDRA
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release 1.4 Based on MedDRA Version 10.1 ICH-Endorsed Guide for MedDRA Users on Data Output 12 September 2007 Copyright ICH Secretariat (c/o IFPMA)
More informationIntroductory Guide MedDRA Version 18.1
Introductory Guide MedDRA Version 18.1 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory
More informationMedDRA - International standard for coding safety information. The Golden Triangle
MedDRA - International standard for coding safety information International Pharmacovigilance Conference Moscow, Russia 10 October 2018 Anna Zhao-Wong, MD, PhD MedDRA MSSO The Golden Triangle (MedDRA)
More informationMedDRA Term Selection: Latest activities of the Points to Consider Working Group
MedDRA Term Selection: Latest activities of the Points to Consider Working Group Patrick Revelle MedDRA MSSO 23 May 2013 Overview The new EU pharmacovigilance legislation broadened the definition of an
More informationMedDRA Coding Quality: How to Avoid Common Pitfalls
MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationMedDRA 10.0 Review. Terminology Files: What you need to know. MedDRA Version 10.0 Terminology Frequency Distribution
MedDRA 10.0 Review MedDRA Version Changes General Remarks Terminology Files: What you need to know MedDRA Version 10.0 Specific Changes Version 10.0 Changes Overview Changes in a Nutshell Changes Highlights
More informationWhat Medical Writers Need to Know About MedDRA
What Medical Writers Need to Know About MedDRA Expert Seminar Series Session 2 40 th EMWA Conference, Dublin 6 May 2015 Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO MedDRA was developed under
More informationMedDRA TERM SELECTION: POINTS TO CONSIDER
MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.10 Based on MedDRA Version 11.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical and Social History
More informationMedDRA: Safety Data Analysis and SMQs
MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
More informationMedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013
MedDRA Coding/ AE Log Item 1 Refresher ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding Overview MedDRA: standardized dictionary of medical terminology Results from ICH initiative to standardize
More informationMedDRA: Safety Data Analysis and SMQs
MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
More informationMedDRA Safety Data Analysis and SMQs
MedDRA Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationSummary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER
Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.8 Based on MedDRA Version 10.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical
More informationCoding with MedDRA 3/6/2019
Coding with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA
More informationAdvanced MedDRA Coding
Advanced MedDRA Coding MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities
More informationFigure 1. Number of spontaneous reports received by Lareb for the NOACs per year for different sources
1.1. Overview of reports on novel oral anticoagulants (NOACs) Introduction Lareb published overviews of reports concerning the novel anticoagulants (NOACs) apixaban (Eliquis ), dabigatran (Pradaxa ) and
More informationFrequently Asked Questions
Welcome to the European MedDRA Users Group Webinar on Update on Medication errors The session will be chaired by Ian Slack Liz Thomas from the MSSO will provide technical support Asking Questions Using
More informationProactivity Proposals
What is proactive MedDRA Maintenance? In part, proactive maintenance means the MSSO may make corrections or improvements to MedDRA that we identify without receiving specific change requests from users.
More informationSupplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
More informationMedDRA Coding and Versioning
MedDRA Coding and Versioning 4th ANNUAL INNOVATIONS IN CLINICAL DATA MANAGEMENT Alexandria, VA. 27-28 October 2016 Anna Zhao-Wong, MD, PhD Deputy Director of MedDRA MSSO anna.zhao-wong@meddra.org Agenda
More informationMedDRA TERM SELECTION: POINTS TO CONSIDER
MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.13 Based on MedDRA Version 20.0 1 March 2017 Disclaimer and Copyright Notice This document is protected by copyright
More informationMedDRA TERM SELECTION: POINTS TO CONSIDER
MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.4 Based on MedDRA Version 15.1 1 October 2012 Disclaimer and Copyright Notice This document is protected by copyright
More informationCoding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH
Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationCoding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA
Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationCreating a User Defined Pneumonia-Specific Syndrome in ESSENCE. Preventive Medicine Directorate September 2016
Creating a User Defined Pneumonia-Specific Syndrome in ESSENCE Preventive Medicine Directorate September 2016 0 Pneumonia-Specific Syndrome NMCPHC retrospective analyses suggest that surveillance using
More informationCoding with MedDRA 3/2/2017
Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities
More informationUpdate overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab
Update overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2017) in consultation
More informationCoding with MedDRA 4/22/2015
Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities
More informationCoding with Confidence
Coding with Confidence Hilary Vass (Global Clinical Dictionary Manager AstraZeneca UK Limited) Tomás Moraleda (Medical Officer MSSO) 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam Netherlands Disclaimer
More informationAPPENDIX EXHIBITS. Appendix Exhibit A2: Patient Comorbidity Codes Used To Risk- Standardize Hospital Mortality and Readmission Rates page 10
Ross JS, Bernheim SM, Lin Z, Drye EE, Chen J, Normand ST, et al. Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. Health Aff (Millwood).
More informationSynopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant
More informationTerminologies for recording of ADR:s
Terminologies for recording of ADR:s 1 Adverse reaction terms? Dizziness SOB. feeling hot.? dyspnoea lightheadedness.? breath shortness. evidence of VEBS on 2 ECG Concepts Terminology collection of accepted
More informationChapter 1: Certain Infectious and parasitic diseases (A00-B99)
ICD-10-CM Part 5 Chapter 1: Certain Infectious and parasitic diseases (A00-B99) New sub-chapter: Infections with a predominantly sexual mode of transmission (A50-A64) You will not find: septicemia - rather,
More informationChapter 10 Respiratory System J00-J99. Presented by: Jesicca Andrews
Chapter 10 Respiratory System J00-J99 Presented by: Jesicca Andrews 1 Respiratory System 2 Respiratory Infections A respiratory infection cannot be assumed from a laboratory report alone; physician concurrence
More informationSession 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016
Session 2 Data analysis based on overview of EudraVigilance data Victoria Newbould, EMA, EU Medication-errors workshop London, 20 October 2016 An agency of the European Union Acknowledgement Steven Le
More informationScottish Clinical Coding Standards
Scottish Clinical Coding Standards Number 17 March 2018 Scottish Clinical Coding Standards ICD-10 Contents Scottish Clinical Coding Standards ICD-10...1 Sepsis...1 Sepsis Use of Z codes...5 Sepsis is a
More informationInnovation and Regulatory Review What is JumpStart?
Innovation and Regulatory Review What is JumpStart? Alan M. Shapiro, MD, PhD, FAAP Office of Computational Science FDA/CDER/OTS May 17, 2017 Disclosure No financial or commercial conflict of interest The
More informationCorporate Medical Policy
Corporate Medical Policy Identification of Microorganisms Using Nucleic Acid Probes File Name: Origination: Last CAP Review: Next CAP Review: Last Review: identification_of_microorganisms_using_nucleic_acid_probes
More informationB3D-MC-GHCY Clinical Study Report Synopsis Page 1Page GHCY Synopsis LY
B3DMCGHCY Clinical Study Report Page 1Page 1 2. GHCY B3DMCGHCY Clinical ClinicalStudy StudyReport Report Page 2Page 2 Clinical Study Report : Study B3DMCGHCY Title of Study: The Effect of Teriparatide
More informationMedDRA TERM SELECTION: POINTS TO CONSIDER
MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.8 Based on MedDRA Version 17.1 1 September 2014 Disclaimer and Copyright Notice This document is protected by copyright
More informationIntroductory Guide for Standardised MedDRA Queries (SMQs) Version 14.0
Introductory Guide for Standardised MedDRA Queries (SMQs) Version 14.0 Acknowledgements Acknowledgements MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers
More informationDaniel C. DeSimone, MD Assistant Professor of Medicine
Daniel C. DeSimone, MD Assistant Professor of Medicine Faculty photo will be placed here Desimone.Daniel@mayo.edu 2015 MFMER 3543652-1 Infective Endocarditis Mayo School of Continuous Professional Development
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin
More informationCoding with MedDRA. Course Overview
Coding with MedDRA MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Course Overview MedDRA background MedDRA s structure, scope,
More informationIntroductory Guide for Standardised MedDRA Queries (SMQs) Version 18.1
Introductory Guide for Standardised MedDRA Queries (SMQs) Version 18.1 Acknowledgements Acknowledgements MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document
More informationAutomatic generation of MedDRA terms groupings using an ontology
Automatic generation of MedDRA terms groupings using an ontology Gunnar DECLERCK a,1, Cédric BOUSQUET a,b and Marie-Christine JAULENT a a INSERM, UMRS 872 EQ20, Université Paris Descartes, France. b Department
More informationCoding with MedDRA 1
Coding with Coding with MedDRA 1 4/3/2015 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
More informationOrientation Program for Infection Control Professionals
Orientation Program for Infection Control Professionals Module 7: Communicable Diseases Table of Contents Module 7: Communicable Diseases... 1 Objectives... 1 Instructions... 1 Overview... 2 Key Concepts...
More informationDiagnostic strategy. Dr Pilar Tornos Hospital Vall d Hebron Barcelona
Diagnostic strategy Dr Pilar Tornos Hospital Vall d Hebron Barcelona Faculty disclosure Pilar Tornos I disclose the following financial relationships: Paid speaker for Recordati, Edwards. Diagnosis of
More informationHow can Natural Language Processing help MedDRA coding? April Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics
How can Natural Language Processing help MedDRA coding? April 16 2018 Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics Summary About NLP and NLP in life sciences Uses of NLP with MedDRA
More informationClinical Decision Seminar Imaging
Cardiology Update 2013, Davos, Switzerland February 2013 Clinical Decision Seminar Imaging Dr. med. Robert Manka Cardiovascular MRI and Interventional Cardiology University Hospital Zurich Institute for
More information2.1 Numerator: The number of denominator continuous inpatient spells (i.e. spells excluding those with a diagnosis
2) Hospital case-fatality 2.1 Numerator: The number of denominator continuous inpatient spells (i.e. spells excluding those with a diagnosis of cancer anywhere in the spell) where the patient dies in hospital
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationAppropriate utilization of the microbiology laboratory. 11 April 2013
Appropriate utilization of the microbiology laboratory 11 April 2013 Lecture Plan Revision of infectious disease Triad of infectious disease Interaction between host and infectious agent Pathogenesis Phases
More informationHPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 39, 2018 (Notification
More informationToward a Diagnosis Driven (Dental) Profession through Controlled Terminology
Toward a Diagnosis Driven (Dental) Profession through Controlled Terminology James J. Cimino, MD Director, Informatics Institute University of Alabama at Birmingham Birmingham, Alabama, USA Los Angeles,
More informationAPR-DRG Description Ave Charge
Abdominal Pain 16,500.25 2.8 6,000.09 Acute & Subacute Endocarditis 15,339.30 3.0 5,113.10 Acute Myocardial Infarction 17,687.46 2.6 6,802.87 Alcohol Abuse & Dependence 19,126.64 4.2 4,553.96 Alcoholic
More informationAuthoring SNOMED CT Generic Authoring Principles. Penni Hernandez and Cathy Richardson Senior Terminologists
Authoring SNOMED CT Generic Authoring Principles Penni Hernandez and Cathy Richardson Senior Terminologists Outline of Tutorial Welcome Examining a request What s been requested Does it belong in SNOMED
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationNursing diagnosis for strep pharyngitis
Nursing diagnosis for strep pharyngitis Acute glomerulonephritis (GN) comprises a specific set of renal diseases in which an immunologic mechanism triggers inflammation and proliferation of. Dec 9, 2015.
More informationUpper Respiratory Tract Infections / 42
Upper Respiratory Tract Infections 1 Upper Respiratory Tract Infections Acute tonsillitispharyngitis Acute otitis media Acute sinusitis Common cold Acute laryngitis Otitis externa Mastoiditis Acute apiglottis
More informationEpisodes of Care Risk Adjustment
Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous
More informationRoutine signal detection and statistical tools on paediatrics
Routine signal detection and statistical tools on paediatrics Paediatric workshop 28 April 2014 Presented by: Cosimo Zaccaria Signal Management Pharmacovigilance Department An agency of the European Union
More informationOOGZIEKTEN VOOR DE HUISARTS F. GOES, JR.
OOGZIEKTEN VOOR DE HUISARTS F. GOES, JR. HET RODE OOG F. GOES, JR. Condition Signs Symptoms Causes Conjunctivitis Viral Normal vision, normal pupil size Mild to no pain, diffuse Adenovirus (most common),
More informationInfection Control Manual Residential Care Part 3 Infection Control Standards IC6: Additional Precautions
IC6: 0110 Appendix I Selection Table Infection Control Manual esidential Care IC6: Additional Legend: outine Practice * reportable to Public Health C - Contact ** reportable by Lab D - Droplet A - Airborne
More information0301 Anemia Others. Endocrine nutritional and metabolic disorders Others Vascular dementia and unspecified dementia
Certain infectious and parasitic diseases 0101 Intestinal infectious diseases 0102 Tuberculosis 0103 Infections with a predominantly sexual mode of transmission 0104 Viral infections characterized by skin
More informationSelected tables standardised to Segi population
Selected tables standardised to Segi population LIST OF TABLES Table 4.2S: Selected causes of death, all-ages, 2000 2004 (Segi Standard) Table 5.3S: Public hospitalisations by major cause of admission
More informationHPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 22, 2018 (Notification
More informationHPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 49, 2018 (Notification
More information